Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
0.96
Ask:
1.10
Spread: 0.14 (14.583%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

AGM Statement

30 Sep 2013 07:00

RNS Number : 1267P
Provexis PLC
30 September 2013
 



30 September 2013

 

Provexis plc

 

AGM Statement

 

Provexis plc ("Provexis" or the "Company"), the business that develops and licenses scientifically-proven functional food, will hold its Annual General Meeting in Reading later today.

 

At the meeting Dawson Buck, the non-executive Chairman of the Company, will give the following update on developments:

 

"The Company has undergone major change during the last year, with the Science in Sport business being demerged from Provexis and the cost base of the legacy Provexis business being significantly reduced. The demerger resulted in a substantial increase in shareholder value.

 

DSM Nutritional Products continues to develop the market actively for our novel, patented Fruitflow® heart-health ingredient in all global markets. Currently, over 20 regional consumer healthcare and dietary supplement brands containing the ingredient are now in the market. The heart-healthy dietary supplement segment is highly competitive and in some markets highly regulated, which requires country by country analysis and marketing strategy development and thus time to gain adoption and achieve success.

 

Much focus has been given to the development of a concentrated, powder version of Fruitflow®, suitable for tablets, gel capsules and other dietary supplements. While manufacturing set up costs of a supply chain to produce this powder will adversely affect cost of goods in the year, this format is regarded as being the required format for brand owners and as such, this investment by DSM is seen as important to the future growth of Fruitflow® revenues in the important dietary supplements sector.

 

Costs in Provexis have been reduced drastically, and together with a recent drawdown of funds, the company has sufficient cash to fund operations until early 2016.

 

With this very focused model and low operating costs, the directors believe the Company is in a strong position."

 

 

-ends-

 

For further information please contact:

 

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 861777

 

Bobbie Hilliam Tel: 020 7397 8900

Cenkos Securities plc

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMFDLFLXKFEBBL
Date   Source Headline
20th May 20267:00 amRNSHolding(s) in Company
16th Apr 202612:37 pmRNSHolding(s) in Company
31st Dec 20258:22 amRNSHalf-year Financial Report
31st Dec 20258:22 amRNSHalf-year Financial Report
21st Nov 20251:38 pmRNSResult of AGM
30th Oct 20257:30 amRNSRestoration - Provexis plc
30th Oct 20257:00 amRNSFinal Results
1st Oct 20257:30 amRNSSuspension - Provexis PLC
30th Sep 20258:40 amRNSDelay in publication of annual accounts
7th Jan 20251:14 pmRNSGrant of Options and Warrants
31st Dec 20241:00 pmRNSTotal Voting Rights
31st Dec 20249:59 amRNSHalf-year Report
18th Dec 20247:00 amRNSPurchase of Fruitflow® II SD & royalty payment
25th Oct 20243:47 pmRNSResult of AGM
30th Sep 20247:00 amRNSFinal Results
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.